Literature DB >> 19544111

Association between MGMT promoter hypermethylation and p53 mutation in glioblastoma.

Jamal Shamsara1, Samaneh Sharif, Sima Afsharnezhad, Marzieh Lotfi, Hamid Reza Raziee, Kamran Ghaffarzadegan, Afshin Moradi, Saeed Rahighi, Javad Behravan.   

Abstract

O(6)-methylguanine-DNA methyltransferase (MGMT) is a DNA repair enzyme that removes alkyl groups from the O(6) position of guanine. MGMT is transcriptionally silenced by promoter hypermethylation in several human neoplasia. We used methylation-specific PCR (MSP) to analyze the MGMT promoter methylation status of 50 glioblastoma tumors. Hypermethylation was detected in 24 of 50 (48%) samples. We also analyzed mutant p53 expression by immunohistochemical analysis of glioblastoma tissue samples. A significant association was found between MGMT methylation and p53 mutation status (p< .05). These results suggested that epigenetic inactivation of MGMT plays an important role in the survival of glioblastoma patients and this inactivated gene involved in p53 mutation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19544111     DOI: 10.1080/07357900902783211

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.176


  14 in total

Review 1.  Epigenetic changes of DNA repair genes in cancer.

Authors:  Christoph Lahtz; Gerd P Pfeifer
Journal:  J Mol Cell Biol       Date:  2011-02       Impact factor: 6.216

Review 2.  MGMT testing allows for personalised therapy in the temozolomide era.

Authors:  A Dullea; L Marignol
Journal:  Tumour Biol       Date:  2015-10-30

3.  TP53 promoter methylation in primary glioblastoma: relationship with TP53 mRNA and protein expression and mutation status.

Authors:  Dorota Jesionek-Kupnicka; Malgorzata Szybka; Beata Malachowska; Wojciech Fendler; Piotr Potemski; Sylwester Piaskowski; Dariusz Jaskolski; Wielislaw Papierz; Wieslaw Skowronski; Waldemar Och; Radzislaw Kordek; Izabela Zawlik
Journal:  DNA Cell Biol       Date:  2014-02-07       Impact factor: 3.311

Review 4.  DNA damage response genes and the development of cancer metastasis.

Authors:  Constantinos G Broustas; Howard B Lieberman
Journal:  Radiat Res       Date:  2014-01-07       Impact factor: 2.841

5.  Pseudoprogression in patients with malignant gliomas treated with concurrent temozolomide and radiotherapy: potential role of p53.

Authors:  Hyun-Cheol Kang; Chae-Yong Kim; Jung Ho Han; Ghee Young Choe; Jae Hyoung Kim; Jee Hyun Kim; In Ah Kim
Journal:  J Neurooncol       Date:  2010-07-15       Impact factor: 4.130

6.  Codeletions at 1p and 19q predict a lower risk of pseudoprogression in oligodendrogliomas and mixed oligoastrocytomas.

Authors:  Andrew L Lin; Jingxia Liu; John Evans; Eric C Leuthardt; Keith M Rich; Ralph G Dacey; Joshua L Dowling; Albert H Kim; Gregory J Zipfel; Robert L Grubb; Jiayi Huang; Clifford G Robinson; Joseph R Simpson; Gerald P Linette; Michael R Chicoine; David D Tran
Journal:  Neuro Oncol       Date:  2013-11-26       Impact factor: 12.300

7.  MGMT methylation assessment in glioblastoma: MS-MLPA versus human methylation 450K beadchip array and immunohistochemistry.

Authors:  S Trabelsi; N Mama; M Ladib; N Karmeni; M Haddaji Mastouri; M Chourabi; M Mokni; K Tlili; H Krifa; M T Yacoubi; A Saad; D H'mida Ben Brahim
Journal:  Clin Transl Oncol       Date:  2015-08-20       Impact factor: 3.405

8.  MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR.

Authors:  Annette Bentsen Håvik; Petter Brandal; Hilde Honne; Hanne-Sofie Spenning Dahlback; David Scheie; Merete Hektoen; Torstein Ragnar Meling; Eirik Helseth; Sverre Heim; Ragnhild A Lothe; Guro Elisabeth Lind
Journal:  J Transl Med       Date:  2012-03-06       Impact factor: 5.531

9.  The clinico-oncologic outcomes of elderly patients with glioblastoma after surgical resection followed by concomitant chemo-radiotherapy.

Authors:  Hee-Kwon Park; Young-Cho Koh; Sang Woo Song
Journal:  Brain Tumor Res Treat       Date:  2014-10-31

10.  Synergistic antioxidant capacity of CsNPs and CurNPs against cytotoxicity, genotoxicity and pro-inflammatory mediators induced by hydroxyapatite nanoparticles in male rats.

Authors:  Israa F Mosa; Mokhtar Youssef; Maher Kamel; Osama F Mosa; Yasser Helmy
Journal:  Toxicol Res (Camb)       Date:  2019-10-22       Impact factor: 3.524

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.